OpGen Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/15/23
OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern TimeGlobeNewsWire • 05/08/23
OpGen's Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FINDGlobeNewsWire • 04/26/23
OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher HealthcareGlobeNewsWire • 04/18/23
OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection PanelGlobeNewsWire • 04/18/23
OpGen's Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnosticsGlobeNewsWire • 04/03/23
CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/30/23
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/29/23
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern TimeGlobeNewsWire • 03/22/23
OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business GrowthGlobeNewsWire • 03/01/23
OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration ProjectGlobeNewsWire • 01/17/23
OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection PanelGlobeNewsWire • 12/13/22